Eli Lilly SG&A Expenses 2010-2024 | LLY
Eli Lilly annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Eli Lilly sg&a expenses for the quarter ending September 30, 2024 were $2.100B, a 16.4% increase year-over-year.
- Eli Lilly sg&a expenses for the twelve months ending September 30, 2024 were $8.094B, a 13.65% increase year-over-year.
- Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
- Eli Lilly annual sg&a expenses for 2022 were $6.44B, a 0.14% increase from 2021.
- Eli Lilly annual sg&a expenses for 2021 were $6.432B, a 5.07% increase from 2020.
Eli Lilly Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$7,403 |
| 2022 |
$6,440 |
| 2021 |
$6,432 |
| 2020 |
$6,121 |
| 2019 |
$6,214 |
| 2018 |
$5,975 |
| 2017 |
$5,982 |
| 2016 |
$6,528 |
| 2015 |
$6,533 |
| 2014 |
$6,621 |
| 2013 |
$7,126 |
| 2012 |
$7,514 |
| 2011 |
$7,880 |
| 2010 |
$7,053 |
| 2009 |
$6,893 |
Eli Lilly Quarterly SG&A Expenses
(Millions of US $) |
| 2024-09-30 |
$2,100 |
| 2024-06-30 |
$2,117 |
| 2024-03-31 |
$1,952 |
| 2023-12-31 |
$1,925 |
| 2023-09-30 |
$1,804 |
| 2023-06-30 |
$1,925 |
| 2023-03-31 |
$1,749 |
| 2022-12-31 |
$1,643 |
| 2022-09-30 |
$1,614 |
| 2022-06-30 |
$1,625 |
| 2022-03-31 |
$1,558 |
| 2021-12-31 |
$1,592 |
| 2021-09-30 |
$1,578 |
| 2021-06-30 |
$1,686 |
| 2021-03-31 |
$1,576 |
| 2020-12-31 |
$1,554 |
| 2020-09-30 |
$1,569 |
| 2020-06-30 |
$1,449 |
| 2020-03-31 |
$1,550 |
| 2019-12-31 |
$1,698 |
| 2019-09-30 |
$1,412 |
| 2019-06-30 |
$1,586 |
| 2019-03-31 |
$1,517 |
| 2018-12-31 |
$1,694 |
| 2018-09-30 |
$1,457 |
| 2018-06-30 |
$1,486 |
| 2018-03-31 |
$1,339 |
| 2017-12-31 |
$1,106 |
| 2017-09-30 |
$1,579 |
| 2017-06-30 |
$1,730 |
| 2017-03-31 |
$1,568 |
| 2016-12-31 |
$1,866 |
| 2016-09-30 |
$1,565 |
| 2016-06-30 |
$1,623 |
| 2016-03-31 |
$1,474 |
| 2015-12-31 |
$1,798 |
| 2015-09-30 |
$1,576 |
| 2015-06-30 |
$1,635 |
| 2015-03-31 |
$1,524 |
| 2014-12-31 |
$1,800 |
| 2014-09-30 |
$1,672 |
| 2014-06-30 |
$1,664 |
| 2014-03-31 |
$1,485 |
| 2013-12-31 |
$1,954 |
| 2013-09-30 |
$1,652 |
| 2013-06-30 |
$1,868 |
| 2013-03-31 |
$1,652 |
| 2012-12-31 |
$1,978 |
| 2012-09-30 |
$1,757 |
| 2012-06-30 |
$1,931 |
| 2012-03-31 |
$1,848 |
| 2011-12-31 |
$2,133 |
| 2011-09-30 |
$1,918 |
| 2011-06-30 |
$2,043 |
| 2011-03-31 |
$1,786 |
| 2010-12-31 |
$1,989 |
| 2010-09-30 |
$1,695 |
| 2010-06-30 |
$1,755 |
| 2010-03-31 |
$1,614 |
| 2009-12-31 |
$1,953 |
| 2009-09-30 |
$1,702 |
| 2009-06-30 |
$1,708 |
| 2009-03-31 |
$1,529 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$789.394B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
